Skip to main content
Fig. 3 | Alzheimer's Research & Therapy

Fig. 3

From: A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer’s Disease

Fig. 3

Time course of CSF catheter sampling and SILK data for Aβ40. Plots show fitted curves for individual patients, with color coding according to doses. Red = placebo, green = 60 mg daily, blue = 60 mg BID, purple = 60 mg TID

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193